Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study

Vincenzo Nasillo,Ambra Paolini,Giovanni Riva,Monica Morselli,Leonardo Potenza,Valeria Coluccio,Monica Maccaferri,Elisabetta Colaci,Valeria Fantuzzi,Andrea Messerotti,Laura Arletti,Valeria Pioli,Elisabetta Lugli,Andrea Gilioli,Chiara Quadrelli,Patrizia Zucchini,Daniela Vallerini,Ivana Lagreca,Patrizia Barozzi,Angela Cuoghi,Paola Bresciani,Roberto Marasca,Maria Teresa Mariano,G. Ceccherelli,Patrizia Comoli,Daniele Campioli,Tommaso Trenti,Franco Narni,Mario Luppi,Fabio Forghieri

Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study

2018

Biosimilars of filgrastim have shown to be comparable to the originator (Neupogen®, Amgen Inc., CA) in terms of pharmacodynamic response in healthy subjects, as well as in overall efficacy and safe...

Keywords:

Biosimilar
Immunology
Filgrastim
Oncology
Stem cell mobilization
Diabetes mellitus
Single Center
Internal medicine
Myeloid leukemia
Retrospective cohort study
Peripheral
Medicine
peripheral blood

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations